In what may be the smallest double-blind, placebo-controlled clinical trials on record, researchers have shown that treating two individuals with drugs aimed at raising brain levels of glycine improved their psychotic symptoms.
Despite its rather specific name, macrophage migration inhibitory factor (MIF) has multiple roles. One of those roles is to serve as a chaperone protein that helps the proper folding of superoxide dismutase (SOD1).
In what may be the smallest double-blind, placebo-controlled clinical trials on record, researchers have shown that treating two individuals with drugs aimed at raising brain levels of glycine improved their psychotic symptoms.
Researchers have shown that by using a combination of genome editing and long-acting slow-effective release antiviral therapy (LASER ART), they were able to eradicate HIV reservoirs and cure nearly 40% of HIV-infected mice.
The Warburg effect – the marked preference of tumors for fueling themselves via anaerobic metabolism – was described more than 90 years ago. Otto Warburg won the Nobel Prize for his discovery in 1931, and research into the phenomenon long dominated the field of tumor metabolism. Over the past decade, however, there has been increased attention to the fact that tumor metabolism is deregulated in multiple ways beyond the Warburg effect.
Scientists from the University of Cambridge have reported that a high proportion of methicillin-resistant Staphylococcus aureus (MRSA) strains were resistant to penicillin-class antibiotics, the beta-lactams, when they were treated with a combination of penicillins and beta-lactamase inhibitors.
Cutting pills in half is currently an act of desperation by those who can't afford the full amount their doctor has prescribed. But for some of the most expensive drugs on the market – cancer drugs – there are a number of drugs where cutting the dose by half, or by more, can result in treatment that is just as effective, and cuts financial toxicity and, possibly, other toxicity risks as well.
One of the highlights of the 2019 annual meeting of the American Society of Clinical Oncology (ASCO) earlier this month were results from the phase III POLO trial, demonstrating that treatment with Lynparza (olaparib, Astrazeneca plc/Merck & Co. Inc.) after platinum chemotherapy nearly doubled the progression-free interval (progression-free survival, PFS) in a group of 154 metastatic pancreatic cancer patients with germline BRCA mutations, from 3.8 months to 7.4 months.
One of the highlights of the 2019 annual meeting of the American Society of Clinical Oncology (ASCO) earlier this month were results from the phase III POLO trial, demonstrating that treatment with Lynparza (olaparib, Astrazeneca plc/Merck & Co. Inc.) after platinum chemotherapy nearly doubled the progression-free interval (progression-free survival, PFS) in a group of 154 metastatic pancreatic cancer patients with germline BRCA mutations, from 3.8 months to 7.4 months.
